Kaléo announces Auvi-Q availability

RICHMOND, Va. — Kaléo on Thursday announced that its Auvi-Q epinephrine auto-injector would be available by prescription starting Feb. 14. Kaléo announced in October that it would be bringing back the auto-injector, which features voice instructions and automatically retracting needle. 

 

“We know how important it is that severely allergic patients have an epinephrine auto-injector that can be with them at all times and used correctly, even without training, during a panic-stricken allergic emergency,” said Dr. Eric Edwards kaléo VP product strategy said. “We are excited to make AUVI-Q, an epinephrine auto-injector with innovative features, available for millions of patients living with severe, life-threatening allergies.”

 

Alongside the availability announcement, kaléo unveiled its Auvi-Q access program, AffordAbility, through which patients with commercial insurance will have an out-of-pocket cost of $0, as will patients without commercial or governmental insurance with a household income of less than $100,000. The cash price for Auvi-Q is $360 and will be available for patients without governmental or commercial insurance. 

 

“We met with patients and physicians and listened to the very real challenges in the current healthcare environment with obtaining access to affordable medicines,” said Spencer Williamson, president and CEO of kaléo.  “As a result, starting February 14, for more than 200 million Americans with commercial insurance, including those with high-deductible plans, the out-of-pocket cost for AUVI-Q will be $0.”

 

Auvi-Q will also be available via a direct delivery service, which can ensure the best expiration dating.